Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Powdermed To Conduct Clinical Trial Of Its Novel DNA-Based H5N1 (Avian) Influenza Vaccine In London

11.07.2006
PowderMed Ltd today announced that it has submitted regulatory documentation to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for permission to conduct a clinical trial to test their proprietary H5N1 or avian influenza (bird flu) vaccine. It is planned that the trial will be conducted at a clinical research unit in London.

This new vaccine is based upon PowderMed’s proprietary system for delivering DNA vaccines – it is a needle-free injection device that fires gold particles coated with DNA (encoding genes specific to the flu strain) at supersonic speed into the immune cells of the skin. This first-time-in-man clinical trial will examine the ability of a vaccine based upon the Vietnam H5N1 avian influenza strain to protect against a potential pandemic form of flu.

A previous study, conducted by PowderMed in the United States, demonstrated that this vaccine technology was able to produce 100% protective immune responses in adult volunteers to a vaccine which encoded an annual influenza strain [Ref 1]. Using bird flu strains this vaccine has also shown 100% protection in various experimental models.

Dr Beadle, PowderMed’s Chief Medical Officer, stated that “This is an exciting opportunity for PowderMed to conduct the first clinical trial on a vaccine which may have a very important role in the event of a future pandemic. We have selected this particular clinical unit in London to conduct the study because they are currently building up a database of volunteers for future influenza studies. This will allow us to conduct the study and get the results as quickly as possible once we have regulatory approval.” Full details of this clinical study and directions for potential volunteers can be found at www.clinicaltrials.gov.

Dr Clive Dix, CEO of PowderMed also added: “Our approach provides a rapid route to vaccine development that can be applied to existing and emerging flu strains including, for example, the threat posed by a pandemic flu strain. DNA vaccines have a huge potential to limit the burden of disease and can be manufactured very rapidly, in large amounts: enough to vaccinate the whole of the UK population twice over (prime and boost) requires just 1Kg of DNA and can be manufactured and available in just three months from the point a strain is identified. We are very excited to see both our annual and pandemic influenza programmes progress through clinical development”.

Christelle Kerouedan | alfa
Further information:
http://www.powdermed.co.uk

More articles from Life Sciences:

nachricht Modern genetic sequencing tools give clearer picture of how corals are related
17.08.2017 | University of Washington

nachricht The irresistible fragrance of dying vinegar flies
16.08.2017 | Max-Planck-Institut für chemische Ökologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Climate change: In their old age, trees still accumulate large quantities of carbon

17.08.2017 | Earth Sciences

Modern genetic sequencing tools give clearer picture of how corals are related

17.08.2017 | Life Sciences

Superconductivity research reveals potential new state of matter

17.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>